To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
VC-backed Kronos Bio goes public
San Mateo, California-based Kronos Bio, a clinical-stage biopharmaceutical company, has raised about $250 million for its IPO after pricing its over 13.1 million shares at $19 per share.
